GMED

Globus Medical, Inc.

$78.96

+4.38% 2026-10-20

Health CareS&P 400

1M 3M 6M 1Y 2Y

GMEDSPY

+3.5%

+6.6%

+3.8%

-15.8%

YTD

-9.6%

+28.2%

Live chart

Loading live chart…

Grades vs sector

Momentum

57th pct in sector

B-

12-1 return: +24.0%
Percentile within its GICS sector across the S&P 1500.

Growth

36th pct in sector

C-

Revenue growth (YoY): +5.9%
Percentile within its GICS sector across the S&P 1500.

Value

75th pct in sector

B+

Forward E/P: 7.0% · EBITDA/EV: 10.3%
Percentile within its GICS sector across the S&P 1500.

Profitability

65th pct in sector

Profit margin: +17.0% · Return on equity: +11.8%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

Zacks · Oct 09

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

Zacks · Oct 08

Key stats

Market cap$10.6B

P/E (trailing)20.2

P/E (forward)14.6

52-week range59.51 – 101.40

Revenue growth (YoY, latest qtr)+5.9%

Dividend yield0.00%

Analyst consensusBuy (13)

Mean price target$100.92 (+28%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Looks undervalued

Model read-out from the numbers below, not advice. Score +5 (DCF counts double).

▲DCF (base case)above the price by 268%

▲Forward P/E vs sector14.6x vs median 17.6x

▲Piotroski F-score8/9

▲Altman Z10.6 (safe)

▲Net debt / EBITDA-0.6x

▲Analyst target+28% (13 analysts)

Discounted cash flow

Bear

$144

+82%

growth 14% · disc. 10.0% · term. 2.0%

Base

$290

+268%

growth 24% · disc. 9.0% · term. 2.5%

Bull

$518

+556%

growth 30% · disc. 8.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 0% a year for 10 years.

Implied

+0%/yr

FCF, last 3 yrs

+78%/yr

FCF, last 5 yrs

+34%/yr

Revenue, last 3 yrs

+42%/yr

Revenue, last 5 yrs

+30%/yr

Same inputs as the DCF above: trailing free cash flow 0.8B, 9.0% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.96 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 28th pct

20.2×
cheaper

Forward P/E

sector median 17.6× · 37th pct

14.6×
cheaper

EV / EBITDA

sector median 15.8× · 24th pct

10.9×
cheaper

Price / sales

sector median 3.1× · 55th pct

3.4×
pricier

Price / book

sector median 3.5× · 28th pct

2.2×
cheaper

FCF yield

sector median 4.1% · 84th pct

7.1%
cheaper

Forward EPS $5.39 vs trailing $3.90 (+38% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

42.4%

Operating margin

20.3%

FCF margin

24.0%

Net margin

17.0%

Return on equity

11.2%

Return on invested capital

12.4%

Net debt / EBITDA

-0.6×

Current ratio

4.6×

Interest cover

–

Cash conversion (OCF/NI)

1.7×

Piotroski F-score 8/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 10.6 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$101

+28%

Analysts

Buy

Range

$84–$125

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$2.9B	$537.9M	$588.8M
2024	$2.5B	$103.0M	$405.2M
2023	$1.6B	$122.9M	$165.2M
2022	$1.0B	$190.2M	$104.4M
2021	$958.1M	$149.2M	$219.4M
2020	$789.0M	$102.3M	$135.1M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +42.2%.

Earnings

Next report: 2026-11-05 · during market · EPS est 1.20

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	1.10	1.34	+21.9%
2026-05-07	0.92	1.12	+21.7%
2026-02-24	1.15	1.28	+11.0%
2025-11-06	0.78	1.18	+51.1%
2025-08-07	0.75	0.86	+14.9%
2025-05-08	0.75	0.68	-9.2%
2025-02-20	0.75	0.84	+12.2%
2024-11-05	0.65	0.83	+28.3%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$789.6M	+5.9%
2026-03-31	$759.9M	–
2025-12-31	$826.4M	–
2025-09-30	$769.0M	–
2025-06-30	$745.3M	–

Analyst actions

RBC Capital

2026-10-01 · main

Outperform → Outperform
PT $85

Wells Fargo

2026-08-07 · main

Overweight → Overweight
PT $99

UBS

2026-07-28 · init

→ Neutral
PT $82

Truist Securities

2026-07-16 · main

Buy → Buy
PT $100

RBC Capital

2026-07-13 · main

Outperform → Outperform
PT $115

BMO Capital

2026-07-09 · init

→ Outperform
PT $94

Insider trades

Tobin James R

Director · 2026-09-15

SELL
$2.2M

Zarrilli Stephen T

Director · 2026-08-18

SELL
$2.2M

None

None · None

SELL
–

Stats refreshed 2026-10-20 18:03:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status